CIRIFOUR

CIRIFOUR

In 2020, Cantargia initiated a second clinical study, the Phase Ib study CIRIFOUR, in which nadunolimab was combined with the checkpoint inhibitor Keytruda® (pembrolizumab), an immunotherapy that is an established standard-of-care treatment for numerous cancers evaluated in the study: non-small cell lung cancer (NSCLC), head and neck cancer (HNSCC) and malignant melanoma.

There is a lot of research to suggest that nadunolimab and immunotherapy may have synergistic effects. In CIRIFOUR, patients who had stopped responding to immunotherapy received nadunolimab in addition to continued dosing with pembrolizumab.

The primary objective of this study was to evaluate the safety of nadunolimab in combination with pembrolizumab and to establish a recommended dose of nadunolimab for this combination. Secondary objectives included evaluation of clinical activity and biomarkers. The study showed an acceptable safety profile, with promising median survival, especially in patients with a high level of infiltrating immune cells in the tumor at the start of treatment. The results were published in Investigational New Drugs in April 2025 and can be found here.

Read more about CIRIFOUR at ClinicalTrials.gov (NCT04452214).